Evidence map›Paper›PMID 29367885›Full record

ArticleNPJ vaccines2018

A heterogeneous human immunodeficiency virus-like particle (VLP) formulation produced by a novel vector system.

Joshua Pankrac, Katja Klein, Paul F McKay, Deborah F L King, Katie Bain, Jason Knapp, Tsigereda Biru, Chanuka N Wijewardhana, Rahul Pawa, David H Canaday and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Effective and targeted latency reversal in CD4Emerging microbes & infections · 2024
    Article
  2. Article
  3. Review
  4. Review
  5. Addressing an HIV cure in LMIC.Retrovirology · 2021
    Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Joshua Pankrac *1Department of Microbiology and Immunology, University of Western Ontario, London, ON N6A 5C1 Canada.
Katja Klein *1Department of Microbiology and Immunology, University of Western Ontario, London, ON N6A 5C1 Canada.
Paul F McKay3Division of Medicine, Department of Infectious Diseases, Imperial College London, Norfolk Place, London, W2 1PG UK.ORCID 0000-0001-5195-6254
Deborah F L King3Division of Medicine, Department of Infectious Diseases, Imperial College London, Norfolk Place, London, W2 1PG UK.
Katie Bain1Department of Microbiology and Immunology, University of Western Ontario, London, ON N6A 5C1 Canada.
Jason Knapp1Department of Microbiology and Immunology, University of Western Ontario, London, ON N6A 5C1 Canada.
Tsigereda Biru2Division of Infectious Diseases, Department of Medicine, Case Western Reserve University, Cleveland, OH 44106 USA.
Chanuka N Wijewardhana1Department of Microbiology and Immunology, University of Western Ontario, London, ON N6A 5C1 Canada.
Rahul Pawa1Department of Microbiology and Immunology, University of Western Ontario, London, ON N6A 5C1 Canada.
David H Canaday2Division of Infectious Diseases, Department of Medicine, Case Western Reserve University, Cleveland, OH 44106 USA.
Yong Gao1Department of Microbiology and Immunology, University of Western Ontario, London, ON N6A 5C1 Canada.
Sarah Fidler4Department of Medicine, Imperial College London, London, UK.
Robin J Shattock3Division of Medicine, Department of Infectious Diseases, Imperial College London, Norfolk Place, London, W2 1PG UK.
Eric J Arts1Department of Microbiology and Immunology, University of Western Ontario, London, ON N6A 5C1 Canada.
Jamie F S Mann1Department of Microbiology and Immunology, University of Western Ontario, London, ON N6A 5C1 Canada.

Funding

WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Alan David Levine · 1994 to 2026
$50.0M
Impact of HIV-1 Fitness on Disease ProgressionR01AI049170 · NIAID · UNIVERSITY OF WESTERN ONTARIO · PI ARTS, ERIC J · 2002 to 2024
$6.8M
HIV-1 Fitness and RecombinationR56AI049170 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ARTS, ERIC J · 2012 to 2012
$400k
Impact of HIV-1 Fitness on Disease ProgressionR21AI049170 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ARTS, ERIC J · 2001 to 2001
$265k
NIAID NIH HHS P30 AI036219NIAID NIH HHS R01 AI049170NIAID NIH HHS R21 AI049170NIAID NIH HHS R56 AI049170
6 · The paper itself

Abstract

First identified as the etiological agent behind Acquired Immunodeficiency Syndrome (AIDS) in the early 1980s, HIV-1 has continued to spread into a global pandemic and major public health concern. Despite the success of antiretroviral therapy at reducing HIV-1 viremia and preventing the dramatic CD4

Identifiers

PMID29367885
PMCPMC5775397

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.